The purpose of this work was to investigate the role of the ubiquitin-proteasome network (UPN) in prostate cancer (PCA) and to elicit potential markers for this disease. The UPN represents a key factor in the maintenance of cellular homoeostasis as a result of its fundamental function in the regulation of intracellular protein degradation. Members of this network have a role in the biology of haematological and solid tumours. Tumour cells and normal epithelial cells from 22 prostatectomy specimens were isolated by laser microdissection. Prostate biopsy samples from healthy individuals served for technical calibration and as controls. Transcript levels of eight selected genes with E3 ubiquitin ligase activity (labelling target proteins for proteasome degradation) and two genes belonging to the proteasome-multienzyme complex itself were analysed by quantitative real-time RT-PCR. The proteasome genes PSMC4 and PSMB5 and the E3 ubiquitin ligase NEDD4L were significantly and coherently upregulated in PCA cells compared with the corresponding adjacent normal prostate tissue. Transcription of the E3 ubiquitin ligase SMURF2 was significantly higher in organ-confined tumours (pT2) compared with non-organconfined cancers (pT3). The results indicate a role for PSMC4 and PSMB5 and the E3 ubiquitin ligase NEDD4L in prostate tumourigenesis, whereas SMURF2 downregulation could be associated with clinical progression. NEDD4L and SMURF2 both target transforming growth factor (TGF)-b for degradation. This reflects the pleiotropic role of the TGF-b signalling pathway acting as a tumour suppressor in normal and pre-cancerous cells, but having oncogenic properties in progressing cancer. Further studies have to elucidate whether these alterations could represent clinically relevant PCA-diagnostic and progression markers.
Introduction
Knowledge about expression patterns of genes involved in the control of cellular homoeostasis is important to understand malign transformation and cancer progression, and could improve cancer diagnosis and staging. Cellular disposal of molecules is essential for normal cellular homoeostasis. The ubiquitin-proteasome network (UPN) is accountable for the selective cellular removal of mis-folded, damaged, and unassembled polypeptide chains and regulatory proteins.
1-2 It regulates numerous basic cellular processes such as cell cycle progression, signal transduction, proliferation, apoptosis, modulation of surface receptors and regulation of tumour suppression proteins [2] [3] [4] ( Figure 1 ). Proteins for proteasome degradation are labelled by conjugation of multiple ubiquitin moieties (ubiquitination). Ubiquitin is an abundant small highly conserved, composed of 76 amino acids, protein found only in eukaryotes, and is transferred by a cascade of three enzyme types: protein E1 activates the C-terminus of the ubiquitin, whereas E2 transfers the activated ubiquitin to one of the multiple E3 ubiquitin ligase proteins. E3 ubiquitin ligases are responsible for the specificity of protein recognition and ubiquitination, thus ensuring the fidelity of selective proteolysis. The proteasome is a 2.2 MDa barrel-shaped multi-catalytic proteinase complex, the 26S proteasome, composed of two complexes, a 20S core particle and a 19S regulator cap. The 20S core contains the protease subunits and is composed of four rings (two identical peripheral alpha rings and two identical central beta rings), each ring containing seven non-identical subunits (resulting in 2 Â 14 non-identical subunits). The 19S cap (alternative name PA700) is made of two sub-complexes, the lid and the base and a total of 17 peptide molecules. It contains 11 non-ATPase subunits and 6 ATPases that unfold the substrates and translocate them into the core for proteolysis (substrate specificity; for further information see http://www.atlasgeneticsoncology. org/Deep/UbiquitininCancerID20083.html). The proteasome is not only found attached to the endoplasmatic reticulum and to the nucleus but is also found free in the cytosol.
1-2 Alterations of this critical degradation machinery have an important role in tumourigenesis and cancer progression. [4] [5] [6] Its hierarchical character further provides a platform for a novel approach in innovative anti-cancer therapy. 5 The aim of this pilot study is a compact analysis of the transcription patterns of selected important 'representatives' of those arms of the UPN that control (prostate) cancer-relevant pathways (eight E3 ubiquitin ligases and two integral members of the proteasome, Table 1 and Figure 1 ). Such findings could provide valuable information on prostate cancer (PCA) biology and further indicate potential diagnostic and prognostic markers.
Materials and methods

Tissue samples, cryosection and laser microdissection
Informed consent from the patients involved in this project and the healthy volunteers (calibrator, see below), as well as the approval from the institutional review board was obtained according to the directions of the German authorities.
A total of 22 PCA patients undergoing radical prostatectomy were included in this study ( Table 2 ; the identical collective has been investigated in an earlier study (see Hellwinkel et al.2009 7 ). None of the patients had been treated with radio-, chemotherapy or ablative hormonal therapy. Tumour and normal tissue samples were taken with a 6-mm punch biopsy instrument from tumourous and non-tumourous areas as described before. 8 The specimens were incubated in RNAlater (Qiagen, Hilden, Germany) at 4 1C for 2 h and then stored for a long term at -80 1C. To select epithelial (tumour and adjacent normal) cells for gene expression analyses, we performed laser microdissection as previously described. [7] [8] First, the specimens were briefly thawed on ice and then cryosections of up to 15 mm thickness were prepared and transferred to RNAse-free membrane slides (PALM Microlaser Technologies AG, Bernried, Germany). The cryosections were air-dried and stained with cresyl violet following standard procedures. Additionally, representative sections were hematoxylin and eosin stained for pathological examination and archival storing. To produce samples of highest uniformity, tissue areas containing either only tumour (always both Gleason components at proportions corresponding to the histopathological data given in Table 2 ) or normal prostate duct cells (1000-3000 mm 2 ) were microdissected and collected employing an ultraviolet laser-based microdissection system (PALM Microlaser Technologies) according to manufacturer's protocols. Microdissected samples Transcription alterations in prostate carcinoma OJC Hellwinkel et al 
RNA extraction and quality control
Collected tissue samples were processed applying the RNeasy Micro Kit (Qiagen) according to manufacturer's protocols. From each sample, 1 ml of the final eluted RNA volume (14 ml) was used for analysis in an Agilent Bioanalyzer microcapillary electrophoresis system (RNA 6000 Pico Kit, Agilent, Waldbronn, Germany).
cDNA synthesis and real-time quantitative (RT)-PCR
From each selected sample, RNA amounts of 20 ng (estimated on the basis of the Bioanalyzer analysis) were reverse transcribed to cDNA in a volume of 20 ml by using random primers and the cDNA archive kit (Applied Biosystems, Darmstadt, Germany) according to manufacturer's protocol. Single-transcript quantitative (q) RT-PCRs were run in 20 ml solutions (in duplicates) on the cDNA equivalent of each 1 ng RNA per sample using the PCR master mix from Applied Biosystems, as indicated by the manufacturer. Assays on demand (Applied Biosystems; each 1ml per PCR sample) were employed as pre-designed primer pair and probe combinations to amplify specifically selected transcripts of the UPN as shown in Table 1 . Hypoxanthine-guanine phosphoribosyl transferase and transferrin receptor as housekeeping genes with low transcription rates served as independent internal controls ('housekeeping' genes). Real-time PCR was run using a Gene-analyser 7900 (Applied Biosystems) on 96-well fast-plates following manufacturer protocols. The relative quantification results (RQs) were calculated using the delta-delta Ct method as specified by the manufacturer; here, RNA from a pool of 25 healthy controls served as calibrator (set as 1; see above).
Statistic evaluation
Each experiment was run in duplicates. Descriptive and basic statistics involved calculation of means and/or medians and 95% confidence intervals. Relative quantification results (RQs; means of transcription levels normalised separately on two housekeeping genes and expressed as x-fold transcription compared with the (healthy control) calibrator set as 1) of all transcripts were first compared between the tumour (RQ(T)) and the corresponding adjacent normal samples (RQ(N)). Non-parametric paired Wilcoxon tests were applied to test differences between these groups for significance. Then, x-fold transcript quantities in tumours compared with the corresponding adjacent normal tissues were calculated by division of individual RQ(T) by RQ(N) values. The resulting RQ(T/N) values were grouped depending on tumour stages (pT2 vs pT3) or histopathological grades (Gleason sum p6 vs Gleason sum X7). Non-parametric unpaired MannWhitney U-tests were applied to test differences between tumour stages or histopathological grades.
Bi-variate analyses were applied to test transcription rates of all genes for correlations (for this purpose, Spearman's r correlation coefficients were calculated).
Transcript level differences were considered to be significant when means of the double housekeeping gene-normalised RQ sets displayed a P value o0.05.
Statistic evaluation was performed using Microsoft Excel and SPSS (SPSS company, Chicago, IL, USA).
Results
Transcription levels in tumour vs adjacent normal tissue
All analysed transcripts could be analysed by real-time RT-PCR in tumour and normal tissues of all samples Transcription alterations in prostate carcinoma OJC Hellwinkel et al (Table 3) . As demonstrated by paired Wilcoxon tests, the proteasome fractions PSMC4 (1.57-fold, Figure 2a ) and PSMB5 (twofold, Figure 2b ) and the E3 ubiquitin ligase NEDD4L (2.75-fold, Figure 2c ), were significantly upregulated in tumour compared with the corresponding adjacent normal tissues. Another E3 ubiquitin ligase, HECW1, was even upregulated by fivefold in tumour cells; however, this result did not meet our significance criteria.
Transcription levels in relation to tumour stage and histology
To evaluate transcription differences in tumours (normalised on adjacent normal tissue) of different clinical stages (pT2 vs pT3) as well as in tumours of varying histopathological appearances (Gleason sum scores p6 vs X7) Mann-Whitney U-tests were applied. Here, only one gene, SMURF2 demonstrated a significantly higher level of transcription in pT2 tumours than in pT3 tumours ( Figure 3) . However, the analysis on tumour histology did not reveal any significant difference in transcript levels among investigated transcripts between Gleason p6 and Gleason X7 tumours (not shown).
Correlation between investigated transcripts
To explore the coherence of transcription in tumour cells, we employed multiple bi-variate analyses of all examined transcripts, and tested correlation coefficients by Spearman's r-tests. All significant correlations were found to be positive, indicating a coherent expression manner of the investigated UPN genes: high positive correlations (Pp0.001) were found between the proteasomal units PSMC4, PSMB5 and the E3 ubiquitin ligase UBE3A and between the E3 ubiquitin ligases UBE3A and CBL or SMURF2, respectively (not shown). As displayed in Figure 4 , transcription rates of PSMC4, PSMB5 and NEDD4L, which demonstrated significant upregulation in tumour cells (Figures 2a-c) , also showed significant positive correlation with each other, signifying consistent and simultaneous expression patterns.
Discussion
The critical role of the ubiquitin-proteasome protein degradation system in cell cycle regulation, proliferation, apoptosis and regulation of tumour suppressor genes makes it a target for oncogenic alterations. 4, 6, 9 The UPN comprises of a large number of components; hundreds of E3 ubiquitin ligases have been described. [10] [11] To obtain compact information, we limited the number of investigated components to 'representatives' of specific UPN Transcription alterations in prostate carcinoma OJC Hellwinkel et al branches, which control important cancer relevant pathways. Our survey of course cannot claim to be exhaustive, but it allows a quantitative assessment of the biological relevance and potential clinical applications of the UPN at the transcription level at a moderate effort. Three of the investigated transcripts, PSMC4, PSMB5 and NEDD4L, showed moderate upregulation in tumours compared with adjacent normal tissue of PC patients (Figures 2a-c, Table 3 ). The mean differences were relatively moderate (approximately between 1.6 and 2.8-fold), but significant even with the limited number of samples of the investigated collective (22 tumour-normal tissue pairs). This annotation permits the suggestion of a possible role in PCA biology.
PSMC4 and PSMB5 are members of the two complexes of the proteasome responsible for recognition and uptake of ubiquitin-tagged substrates into the proteasome (19S regulatory complex) and their ATP-dependent proteolysis (20S core complex), respectively. Overexpression of these genes would enhance proteosomal degradation of some critical cellular regulatory proteins, including tumour suppressors and modulators of apoptosis. Thus, the inhibition of the proteasome represents a promising strategy for cancer therapy. In recent studies, proteasome inhibitors display proapoptotic effects. 5, [12] [13] The first proteasome inhibitor (bortezomib, Velcade, PS-341) has now been approved for the treatment of advanced multiple myeloma. [14] [15] Additionally, trials for other haematological and solid tumours, including PCA have been initiated. [16] [17] [18] [19] NEDD4L acts as an E3 ubiquitin ligase, and thereby regulates diverse cellular processes such as excretion, plasma membrane channel regulation, protein catabolism and TGF-b signalling. NEDD4L negatively regulates TGF-b signalling by ubiquitination of TGF-b receptor type I (TGFb-R1) and Smad2. 20 TGF-b (TGF-b1) itself is a pleiotropic growth factor with tumour suppressor activity in normal prostate epithelia, which maintains epithelial homoeostasis by inhibiting cell proliferation, stimulating cell differentiation and inducing apoptosis. [21] [22] [23] [24] The upregulation of NEDD4L transcription and subsequently increased protein levels in PCA cells found here would suggest higher tagging of its substrate TGF-bR1 for ubiquitination and subsequent proteasome degradation, and thus decrease the protein levels of its targets. This would result in downregulation of the TGF-b cascade and its tumour suppressive functions. Furthermore, pre-clinical models suggest an androgen responsiveness of NEDD4L. 25 However, the effect of androgens on the ubiquitine network has not been validated in functional studies.
In an earlier study, Hu et al. 26 described downregulation of NEDD4L protein levels in prostate cancer. At the first instance, this observation appears to be contradictory to our results. However, we have to take into account that Hu et al. compared their PCA collective with cancer-adjacent and cancer-free BPH samples. Now, PCA represents a proliferative aberration dissimilar from benign hyperplasia; it does not develop from BPH. It is consequently quite problematic to state a downregulation of NEDD4L expression during carcinogenesis on the basis of a comparison between BPH and PCA only (as done by Hu et al.) . In contrast, we compared PCA and cancer-adjacent histologically normal prostate glands (not BPH). This applies better to the hypothesis of an orthotopic and endogenous appearance of PCA foci from histologically normal prostate gland tissues (eventually because of field cancerization 27 ), and allows feasible conclusions on the natural history of gene transcription in PCA. Thus, a direct comparison of the study from Hu et al. and our own analysis is not viable.
PSMC4, PSMB5 and NEDD4L displayed a remarkable co-transcription (Figure 4) , indicating contiguously enhanced protein levels of these genes. This suggests an increased ubiquitination of substrate proteins of NEDD4L (and other E3 ubiquitin ligases), which is linked with a coherently augmented degradation capacity-demonstrating the coherence of expression rates of many genes belonging to the UPN. A putative common regulation mechanism of the UPN could be a target for selective treatment strategies of PCA.
Only one transcript could discriminate transcription levels at different clinical tumour stages: SMURF2 displayed moderate but significantly enhanced transcription level in pT2 tumours compared with the higher pT3 stage (Figure 3 ). This would suggest that different protein levels of SMURF2 are required at different stages of tumour progression. SMURF2 targets Smads 1, 2, 3 and 7, as well as Smurf1 for ubiquitination and degradation and is (consequently) also a negative regulator of TGF-b signalling. [28] [29] [30] [31] [32] [33] At the first view, it appears illogical that an inhibitor of the TGFb-pathway-which is known to have tumour-suppressive properties in normal prostate (see above)-is seemingly fairly downregulated in progressing tumour. In this respect, it has to be reminded that TGF-b possesses pleiotropic properties. In malignant prostate cells, it Transcription alterations in prostate carcinoma OJC Hellwinkel et al promotes tumour growth, induces angiogenesis, supports extracellular matrix modification and inhibits host immunosuppression. [21] [22] [23] 34, 35 A downregulation of SMURF2, thus should support the oncogenic TGF-b action in malignant cells.
From clinical point of view, this work was carried out on a small but histologically well-defined (laser microdissection) tumour cohort and acts as a pilot study. The results justify further exhaustive screening studies on all known members of the UPN. Independently, the next obligatory step is to analyse the protein levels of those genes found here to be differentially transcribed.
Immunhistochemistry could provide such information in situ-however (in contrast to RNA-studies) only semiquantitatively and with a certain interpretative ambiguity. Thus, tissue microarrays on large tumour cohorts along with comprehensive statistical analyses are mandatory to achieve a sufficient confidence of protein expression surveys by immunhistochemistry. Such studies will clarify the diagnostic and therapeutic relevance of the provided results.
Conclusion
Parts of the UPN (PSMC4, PSMB5 and NEDD4L) demonstrated significant and coherent gene expression upregulation in PCA cells. SMURF2 seems to be downregulated during clinical progression. Dysregulation of these genes display a potential role in prostate tumourigenesis and progression, and could be further applied in diagnostic and therapeutic strategies.
